Patents Assigned to AstraZeneca
  • Method For Diagnosing Multiple Sclerosis
    Publication number: 20080171394
    Abstract: The present invention relates to methods for diagnosing multiple sclerosis in a subject, the method, comprising determining the level of phosphorylation of a marker in a biological sample from the subject, wherein the marker is selected from ?1-antitrypsin (a1AT) and vitamin D binding protein (VDBP); and comparing the level of phosphorylation of the marker in the sample to a reference value.
    Type: Application
    Filed: July 10, 2006
    Publication date: July 17, 2008
    Applicant: AstraZeneca AB
    Inventors: Bodil Eriksson, Bo Franzen, Jan Ottervald
  • Compounds
    Publication number: 20080171770
    Abstract: The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: December 21, 2006
    Publication date: July 17, 2008
    Applicant: AstraZeneca AB
    Inventors: Yevgeni Besidski, Martin Nylof, Inger Kers, Karin Skogholm, Shawn Johnston, Paul Jones, Denis Lebrecque, Andrew Griffin
  • CHEMICAL COMPOUNDS
    Publication number: 20080171734
    Abstract: The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
    Type: Application
    Filed: October 22, 2007
    Publication date: July 17, 2008
    Applicant: AstraZeneca AB
    Inventors: Leonie Campbell, Kurt Gordon Pike, Abid Suleman, Michael James Waring
  • Transcutaneous immunostimulation
    Publication number: 20080171743
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
    Type: Application
    Filed: August 23, 2007
    Publication date: July 17, 2008
    Applicant: AstraZeneca AB
    Inventors: Maurice Raymond Verschoyle Finlay, Jeffrey Morris, Kurt Gordon Pike
  • New Compounds 391
    Publication number: 20080171771
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: June 13, 2007
    Publication date: July 17, 2008
    Applicants: AstraZeneca AB, Astex Therapeutics Ltd
    Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jorg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Ohberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
  • 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3
    Patent number: 7399780
    Abstract: The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: July 15, 2008
    Assignee: AstraZeneca AB
    Inventors: Stefan Berg, Sven Hellberg, Martin Nylöf, Yafeng Xue
  • Method For Assessing the Predisposition and/or Susceptibility to Copd by Analysing Fgf-Bp1
    Publication number: 20080167326
    Abstract: The present invention relates to the discovery of an association between the gene encoding FGF-BP1 (fibroblast growth factor-binding protein) and chronic obstructive pulmonary disease (COPD). The invention identifies a role for FGF-BP1 in COPD. The present invention therefore relates to diagnostic techniques for the detection of COPD by detecting all or part of this gene, its precursors or products (mRNA, cDNA, genomic DNA, or protein). The present invention also provides methods and as-says for identifying compounds which modulate FGF-BP1 and which may be used for treating respiratory diseases such as COPD. Furthermore, the invention relates to polymorphisms in the genes encoding FGF-BP1. The invention also relates to the use of polymorphisms in the FGF-BP1-encoding genes in assessing predisposition and/or susceptibility of an individual to chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: April 3, 2006
    Publication date: July 10, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Witte Koopmann, Simon Smith
  • Pyrimidine Derivatives for Use as Anticancer Agents
    Publication number: 20080167297
    Abstract: A compound of formula (I), wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.
    Type: Application
    Filed: March 31, 2006
    Publication date: July 10, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Andrew Peter Thomas, Thorsten Nowak
  • Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines
    Publication number: 20080167488
    Abstract: The present invention relates to a process of preparing a compound of formula II, wherein R1, n, m and p are defined in the specification.
    Type: Application
    Filed: July 26, 2006
    Publication date: July 10, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Maxime Tremblay
  • 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
    Patent number: 7396834
    Abstract: Compounds of general formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: July 8, 2008
    Assignee: AstraZeneca AB
    Inventors: William Brown, Andrew Griffin, Niklas Plobeck, Christopher Walpole
  • Oxazolidinone and/or isoxazoline as antibacterial agents
    Patent number: 7396847
    Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in (I) wherein C is for example wherein A and B are independently selected from R2a to R3b are independently selected from hydrogen and fluorine; R1a and R1b are independently selected from, for example, hydroxy, —NHC(?W)R4, wherein W is O or S; R4 is, for example, hydrogen, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsaturated heterocyclic ring; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: July 8, 2008
    Assignee: AstraZeneca AB
    Inventors: Michael Barry Gravestock, Neil James Hales, Michael Lingard Swain, Sheila Irene Hauck, Stuart Dennett Mills
  • 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
    Publication number: 20080161278
    Abstract: A compound of formula (I): wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.
    Type: Application
    Filed: March 21, 2006
    Publication date: July 3, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Andrew Peter Thomas, Thorsten Nowak
  • Bicalutamide for Delivering Increasing Steady State Plasma Levels
    Publication number: 20080161404
    Abstract: The present invention relates to a method of treating a metastatic prostate cancer patient by administering to said patient an effective amount of a bicalutamide (4?-cyano-??,??,??-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide) containing formulation capable of delivering at least a mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml; and to bicalutamide containing products and formulations capable of delivering the at least mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml to a patient in need thereof.
    Type: Application
    Filed: February 21, 2006
    Publication date: July 3, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Joseph Carroll, Thomas Meredydd Morris, Ian Derek Cockshott, Bo-Eric Persson, Paul Alfred Dickinson
  • Compounds 620
    Publication number: 20080161269
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: December 19, 2007
    Publication date: July 3, 2008
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Stefan Berg, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Jan-Erik Nystrom, Fernando Sehgelmeble, Peter Soderman
  • Chemical Process
    Publication number: 20080161565
    Abstract: Process for preparing compounds of Formula (I); and (IV); are described.
    Type: Application
    Filed: February 17, 2005
    Publication date: July 3, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
  • Pyrimidines as Igf-I Inhibitors
    Publication number: 20080161330
    Abstract: A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.
    Type: Application
    Filed: March 31, 2006
    Publication date: July 3, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Andrew Peter Thomas
  • Chemical process
    Patent number: 7393962
    Abstract: The present invention provides a process for the preparation of a compound of formula (I): wherein R1 is C1-6 alkyl; R2 and R3 are, independently, C1-6 alkyl; and R4 is C1-6 alkyl or benzyl (wherein the phenyl ring of benzyl is optionally substituted by nitro, S(O)2(C1-4 alkyl), cyano, C1-4 alkyl, C1-4 alkoxy, C(O)(C1-4 alkyl), N(C1-6 alkyl)2, CF3 or OCF3); the process comprising reacting a compound of formula (II): wherein R2, R3 and R4 are as defined above, with a suitable base; and reacting the product so formed with R1OC(O)CH2X, wherein R1 is as defined above and X is chloro, bromo or iodo; wherein the process is carried out in a suitable solvent at a temperature in the range ?40° C. to ?5° C.; and wherein at least 0.2 moles of the compound of formula (II) are used in the process.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: July 1, 2008
    Assignee: AstraZeneca AB
    Inventor: Vahak Abedi
  • Thienopyrimidinedinones and their use in modulation of autoimmune disease
    Patent number: 7393854
    Abstract: The invention relates to thienopyrimidinediones of formula (I): wherein: R1, R2, Q are as defined in the specification, and Ar and Ar2 are selected from certain aromatic ring systems which may be optionally substituted, as defined in the specification. Processes for the preparation of compounds of formula (I), pharmaceutical compositions containing them and their use in therapy are also described and claimed.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: July 1, 2008
    Assignee: AstraZeneca AB
    Inventors: Simon David Guile, Anthony Howard Ingall
  • Adamantyl Derivates as P2x7 Receptor Antagonists
    Publication number: 20080153850
    Abstract: The invention provides compounds of formula (I) pharmaceutically acceptable salt or solvate thereof, in which R1, A1, m and A are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.
    Type: Application
    Filed: August 29, 2005
    Publication date: June 26, 2008
    Applicant: AstraZeneca AB
    Inventors: Rhonan Ford, Barrie Martin, Toby Thompson, Nicholas Tomkinson, Paul Willis
  • NOVEL COMPOUNDS
    Publication number: 20080153812
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: December 18, 2007
    Publication date: June 26, 2008
    Applicant: ASTRAZENECA AB
    Inventors: David Buttar, Kevin Micheal Foote, Maria-Elena Theoclitou, Andrew Peter Thomas